1609545-77-8

Upstream product

• 40296-46-6 ethyl 4,6-dichloronicotinate 
• 73027-79-9 4,6-dichloro-nicotinic acid 
• 65973-52-6 methyl 4,6-dichloropyridine-3-carboxylate 
• 1609530-95-1 4,6-dichloro-N-methylnicotinamide 

Downstream Products

• 1609544-09-3 6-((5-cyano-2-pyridinyl)amino)-4-(((1S,2S)-2,3-dihydroxy-1-phenylpropyl)amino)-N-methylnicotinamide 
• 1610017-77-0 C₂₃H₂₃N₅O₃S 

Relevant academic research and scientific papers

Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors

The identification of small molecule inhibitors of IRAK4 for the treatment of autoimmune diseases has been an area of intense research. We discovered novel 4,6-diaminonicotinamides which potently inhibit IRAK4. Optimization efforts were aided by X-ray crystal structures of inhibitors bound to IRAK4. Structure activity relationship (SAR) studies led to the identification of compound 29 which exhibited sub-micromolar potency in a LTA stimulated cellular assay.

HETEROARYL SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE MODULATORS

Compounds having the following formula (I) or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein R2 is a monocyclic heteroaryl group, and R1, R3, R4, R5 and R6 are as defined herein, are useful as kinase modulators, including IRAK-4 inhibition.